Skip to content

PharmaTopo™

  • Home
  • About PharmaTopo.com
  • Disclaimer for PharmaTopo™
× Close Menu
Open Menu

Tag: Pharma Economics

September 11, 2023

Trends in Pharmaceutical Autoinjector Design and Use

Clinical, CMC, Parenteral Drugs, Patent, Pharma Economics, Pharmaceutical Development, Pharmaceutical Manufacturing, Pharmacy, Planning, Pre-Clinical

Stuart R. Gallant, MD, PhD In today’s post, some important aspects of development and manufacture of combination products with pharmaceutical autoinjectors are considered.  Pharmaceutical autoinjectors…

Stuart Gallant
August 9, 2023

What The Washington Post Got Wrong About Doctors

Finance, Insurance, Medical, Pharma Economics

Stuart R. Gallant, MD, PhD The Washington Post just published an article by Andrew Van Dam, “How much money do doctors really make and why…

Stuart Gallant
June 19, 2023

Leased Lab Space

Finance, Logistics, Pharma Economics, Pharmaceutical Development, Planning

Stuart R. Gallant, MD, PhD In the last two decades, startup pharmaceutical companies have become increasingly frugal with investment capital.  One of the ways to…

Stuart Gallant
January 18, 2023

Solving Drug Shortages

CMC, Finance, Marketed Products, Pharma Economics, Pharmaceutical Manufacturing, Pharmacy, Planning, Portfolio Management, Risk Management

Stuart R. Gallant, MD, PhD Imagine that you have an infection, and you need a common antibiotic, but you cannot find a drugstore that is…

Stuart Gallant
October 20, 2022

Vaccines for Lyme Disease

Clinical, Marketed Products, Parenteral Drugs, Pharma Economics, Pharmaceutical Development, Pharmacy, Vaccine

Stuart R. Gallant, MD, PhD In 1991, Helmut and Erika Simon, two German tourists hiking in the Alps near the Austrian/Italian border when they saw…

Stuart Gallant
September 29, 2022

Pharmaceutical Product Launch

CMC, Insurance, Marketed Products, Medical, Patent, Pharma Economics, Pharmaceutical Development, Pharmaceutical Manufacturing, Pharmacy, Planning

Stuart R. Gallant, MD, PhD Above is a photo from the 1947 launch of the M.V. St. Essylt at J.L. Thompson and Sons was a…

Stuart Gallant
September 24, 2022

Anti-TNF Medications

Clinical, Finance, Marketed Products, Medical, Parenteral Drugs, Patent, Pharma Economics, Pharmaceutical Development, Pharmacy

Stuart R. Gallant, MD, PhD I have a weakness for old Hollywood movies.  The movie still that appears above this paragraph depicts John Carradine in…

Stuart Gallant
August 25, 2022

Pharmaceutical Design Focus:  Clot Busters (2 of 2)

Clinical, CMC, Finance, Marketed Products, Medical, Parenteral Drugs, Patent, Pharma Economics, Pharmaceutical Development, Pharmaceutical Manufacturing, Pharmacy, Portfolio Management, Raw Materials

Stuart R. Gallant, MD, PhD In the first part of this post, we looked at urokinase.  In the second part, we will look at tissue…

Stuart Gallant
August 25, 2022

Pharmaceutical Design Focus:  Clot Busters (1 of 2)

Clinical, CMC, Finance, Marketed Products, Medical, Parenteral Drugs, Patent, Pharma Economics, Pharmaceutical Development, Pharmaceutical Manufacturing, Pharmacy, Portfolio Management, Raw Materials

Stuart R. Gallant, MD, PhD This November will be the 35th anniversary of the approval of tissue plasminogen activator (tPA, alteplase) a leading treatment for…

Stuart Gallant
August 14, 2022

Amazon’s Push Into Healthcare

Finance, Insurance, Medical, Pharma Economics, Pharmacy

Stuart R. Gallant, MD, PhD I was intrigued by Amazon’s recent purchase of One Medical for $3.9B in cash. Amazon is implementing a strategy to…

Stuart Gallant
August 6, 2022

Pharmaceutical Decision Making and Fundraising

Clinical, Finance, Pharma Economics, Pharmaceutical Development, Planning, Portfolio Management, Pre-Clinical, Risk Management, Uncategorized

Stuart R. Gallant, MD, PhD Within pharmaceutical development, there are two types of go-no-go decisions:  1) clinical and 2) financial.  These decisions are linked together…

Stuart Gallant
March 27, 2022

Payment for Pharmaceuticals

Insurance, Marketed Products, Pharma Economics, Pharmacy

Stuart R. Gallant, MD, PhD The United States has a mixed public and private insurance system for health care.  Payments for pharmaceuticals are provided through…

Stuart Gallant
March 22, 2022

Pharmaceutical Design Focus:  Factor VIII (2 of 2)

Clinical, CMC, Finance, Marketed Products, Parenteral Drugs, Patent, Pharma Economics, Pharmaceutical Manufacturing

Stuart R. Gallant, MD, PhD In the first part of this two-part post, we looked at the biochemistry of clotting factor Factor VIII and the…

Stuart Gallant
March 22, 2022

Pharmaceutical Design Focus:  Factor VIII (1 of 2)

Marketed Products, Parenteral Drugs, Pharma Economics, Pharmaceutical Manufacturing

Stuart R. Gallant, MD, PhD Today’s post is a big story involving genetic engineering, pharmaceuticals, intellectual property, and economics.  You will recall from the first…

Stuart Gallant
March 6, 2022

Financial Metrics of Pharmaceutical Companies (2 of 2)

Finance, Pharma Economics, Pharmaceutical Manufacturing

Stuart R. Gallant, MD, PhD In the second part of this two-part post, the topic of valuation will be discussed, followed by how some of…

Stuart Gallant
March 6, 2022

Financial Metrics of Pharmaceutical Companies (1 of 2)

Finance, Pharma Economics, Pharmaceutical Manufacturing

Stuart R. Gallant, MD, PhD This two-part post looks at pharmaceutical companies and how they are financially structured to survive in a competitive market, to…

Stuart Gallant
February 5, 2022

Pharmaceutical Design Focus:  Insulin

Marketed Products, Parenteral Drugs, Pharma Economics, Pharmaceutical Manufacturing

Stuart R. Gallant, MD, PhD Insulin is a subject on a lot of people’s minds—C&E News just came out with a cover story on insulin…

Stuart Gallant
January 7, 2022

The Value of Medications (2 of 2)

Pharma Economics

Stuart R. Gallant, MD, PhD This is the second post in a two-part series on the value of medications.  In this post, we bite the…

Stuart Gallant
January 7, 2022

The Value of Medications (1 of 2)

Pharma Economics

Stuart R. Gallant, MD, PhD This post is the first in a two-part series on the value medications.  “The Value of Medications” is a bit…

Stuart Gallant
December 27, 2021

Nonclinical and CMC (3 of 3)

Analytical, CMC, Parenteral Drugs, Pharma Economics, Pharmaceutical Manufacturing, Pre-Clinical

Stuart R. Gallant, MD, PhD Non-clinical development has two chief goals:  1) to develop safety data enabling the entry of the medicine into human clinical…

Stuart Gallant
December 18, 2021

Intellectual Property (2 of 3)

Clinical, Patent, Pharma Economics, Pharmaceutical Manufacturing, Royalty

Stuart R. Gallant, MD, PhD Licensors and Licensees As discussed in Part 1 of this three-part series, drug development and licensing has taken on the…

Stuart Gallant
December 8, 2021

Cost of Pre-Clinical Development (1 of 3)

Clinical, Pharma Economics, Pharmaceutical Manufacturing, Pre-Clinical

Stuart R. Gallant, MD, PhD In the last three decades, how pharmaceutical drug development occurs has changed dramatically.  Prior to this change, a significant share…

Stuart Gallant

Search

Archives

  • March 2025
  • February 2025
  • January 2024
  • October 2023
  • September 2023
  • August 2023
  • June 2023
  • April 2023
  • March 2023
  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021

Recent Posts

  • Preparation of an Investigational New Drug (IND) Application
  • The 4 Axes of Drug Development Readiness
  • Vaccine Hesitancy
  • Plant-Based Drug Discovery—Nature’s Pharmacy
  • Wound Care and Healing

Recent Comments

    Archives

    • March 2025
    • February 2025
    • January 2024
    • October 2023
    • September 2023
    • August 2023
    • June 2023
    • April 2023
    • March 2023
    • January 2023
    • November 2022
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021

    Categories

    • Analytical
    • Antibiotics
    • Clinical
    • CMC
    • Covid-19
    • Dermatology
    • Endocrine
    • Finance
    • Insurance
    • Knowledge
    • Logistics
    • Marketed Products
    • Medical
    • Oral Drugs
    • Parenteral Drugs
    • Patent
    • Pharma Economics
    • Pharmaceutical Development
    • Pharmaceutical Manufacturing
    • Pharmacy
    • Planning
    • Portfolio Management
    • Pre-Clinical
    • Raw Materials
    • Risk Management
    • Royalty
    • Uncategorized
    • Vaccine

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2025 PharmaTopo™
     / Theme: Really Simple / License: GPLv3